Surrozen (SRZN) Stock Forecast & Price Target

Surrozen is attractive because its lead asset SZN-8141 targets a large unmet need in retinal disease with a differentiated bifunctional design that combines Wnt activation and VEGF inhibition, aiming to improve vascular repair, reduce leakage, and extend durability versus single-mechanism therapies. The recent Merck BRUNELLO read-through provides external validation for Wnt biology in DME, while Surrozen’s own IP position was reinforced by the PTAB denial of the challenge to its ‘278 patent, reducing competitive and legal risk. Fundamentally, the investment case is strengthened by a clear clinical path with IND submission anticipated by the end of 3Q26, DUET initiation by year-end 2026, and a model-based increase in development probability from 15% to 20% for SZN-8141/8143 in DME.

Surrozen is a clinical-stage biotechnology company with no approved products and a capital-intensive pipeline, so its value depends heavily on successful development of SZN-8141, SZN-413, and SZN-8143 in indications such as wet AMD and DME. The latest quarter highlights the strain of that model, with $9.3M of R&D expense, $6.1M of G&A expense, and a net loss of $127.5M, or $11.65 per diluted share, underscoring weak current earnings power. Although it held $106.9M in cash and equivalents as of March 31, 2026, the company still faces meaningful risks around financing, clinical execution, and whether its programs can achieve the commercial assumptions embedded in the valuation.